Jazz Pharmaceuticals plc financial data

Symbol
JAZZ on Nasdaq
Location
Dublin
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 240% % -9.3%
Quick Ratio 30% % -25%
Return On Assets -3% % -180%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,765,116 shares 0.51%
Common Stock, Shares, Outstanding 60,631,000 shares -2.6%
Entity Public Float $6,413,308,100 USD -16%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 60,696,000 shares -1.2%
Weighted Average Number of Shares Outstanding, Diluted 61,606,000 shares -2.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $4,157,833,000 USD 4.1%
Costs and Expenses $4,651,838,000 USD 39%
Operating Income (Loss) $494,005,000 USD -176%
Income Tax Expense (Benefit) $335,318,000 USD -403%
Net Income (Loss) Attributable to Parent $368,484,000 USD -180%
Earnings Per Share, Basic -6 USD/shares -181%
Earnings Per Share, Diluted -6 USD/shares -188%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,326,070,000 USD -40%
Accounts Receivable, after Allowance for Credit Loss, Current $764,364,000 USD 5.6%
Inventory, Net $483,111,000 USD -10%
Other Assets, Current $315,441,000 USD -11%
Assets, Current $3,755,878,000 USD -14%
Deferred Income Tax Assets, Net $846,168,000 USD 45%
Operating Lease, Right-of-Use Asset $61,204,000 USD -21%
Intangible Assets, Net (Excluding Goodwill) $4,565,737,000 USD -11%
Goodwill $1,827,483,000 USD 1.3%
Other Assets, Noncurrent $103,068,000 USD 37%
Assets $11,356,485,000 USD -7.3%
Accounts Payable, Current $152,227,000 USD 78%
Accrued Liabilities, Current $1,001,556,000 USD 17%
Liabilities, Current $2,274,102,000 USD 121%
Deferred Income Tax Liabilities, Net $629,033,000 USD -21%
Operating Lease, Liability, Noncurrent $53,426,000 USD -25%
Other Liabilities, Noncurrent $108,912,000 USD -1.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $569,898,000 USD 5.6%
Retained Earnings (Accumulated Deficit) $442,725,000 USD -53%
Stockholders' Equity Attributable to Parent $3,959,030,000 USD -5.1%
Liabilities and Equity $11,356,485,000 USD -7.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $429,784,000 USD 61%
Net Cash Provided by (Used in) Financing Activities $813,466,000 USD -1338%
Net Cash Provided by (Used in) Investing Activities $168,931,000 USD 38%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 60,631,000 shares -2.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $550,918,000 USD -776%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,326,070,000 USD -40%
Deferred Tax Assets, Valuation Allowance $509,190,000 USD 63%
Deferred Tax Assets, Gross $1,581,516,000 USD 19%
Operating Lease, Liability $53,269,000 USD -32%
Depreciation $10,425,000 USD 36%
Payments to Acquire Property, Plant, and Equipment $13,881,000 USD 101%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $334,985,000 USD -137%
Lessee, Operating Lease, Liability, to be Paid $62,884,000 USD -30%
Operating Lease, Liability, Current $14,331,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Two $12,596,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year One $16,574,000 USD -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 19%
Deferred Income Tax Expense (Benefit) $43,833,000 USD 34%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,615,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $10,314,000 USD -27%
Deferred Tax Assets, Operating Loss Carryforwards $307,413,000 USD 3.7%
Unrecognized Tax Benefits $125,978,000 USD 2.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four $9,020,000 USD -29%
Amortization of Intangible Assets $643,822,000 USD 3.8%
Deferred Tax Assets, Net of Valuation Allowance $1,072,326,000 USD 5.6%
Share-based Payment Arrangement, Expense $290,469,000 USD 26%